Scarica l'app Stockscreener
4.59
4.18%
-0.20
Dopo l'orario di chiusura:
4.68
0.09
+1.96%
Precedente Chiudi:
$4.79
Aprire:
$4.8
Volume 24 ore:
36,941
Relative Volume:
1.26
Capitalizzazione di mercato:
$32.15M
Reddito:
-
Utile/perdita netta:
$-101.87M
Rapporto P/E:
-3.2553
EPS:
-1.41
Flusso di cassa netto:
$-83.46M
1 W Prestazione:
+4.32%
1M Prestazione:
+9.29%
6M Prestazione:
-32.00%
1 anno Prestazione:
-33.88%
Intervallo 1D:
$4.525
$4.8566
Intervallo di 1 settimana:
$4.40
$5.00
Portata 52W:
$3.6201
$9.18
Kezar Life Sciences Inc Stock (KZR) Company Profile
Nome
Kezar Life Sciences Inc
Settore
Industria
Telefono
650-822-5600
Indirizzo
4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Confronta KZR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KZR
Kezar Life Sciences Inc
|
4.59 | 32.15M | 0 | -101.87M | -83.46M | -1.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Kezar Life Sciences Inc Stock (KZR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-08-11 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-03-16 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2021-12-08 | Iniziato | Wells Fargo | Overweight |
| 2018-07-16 | Iniziato | Jefferies | Buy |
| 2018-07-16 | Iniziato | Wells Fargo | Outperform |
| 2018-07-16 | Iniziato | William Blair | Outperform |
Mostra tutto
Kezar Life Sciences Inc Borsa (KZR) Ultime notizie
Kezar Life Sciences, Inc. (NASDAQ:KZR) Shares Sold by Millennium Management LLC - Defense World
Two Sigma Investments LP Cuts Holdings in Kezar Life Sciences, Inc. (NASDAQ:KZR) - Defense World
(KZR) On The My Stocks Page - news.stocktradersdaily.com
Northern Trust Corp Reduces Stock Position in Kezar Life Sciences, Inc. (NASDAQ:KZR) - Defense World
Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference 2025 - BioSpace
When (KZR) Moves Investors should Listen - news.stocktradersdaily.com
Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference - The Joplin Globe
Kezar Life Sciences (KZR) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Kezar Life Sciences Reports Positive Trial Results - TipRanks
Where are the Opportunities in (KZR) - news.stocktradersdaily.com
Dimensional Fund Advisors LP Takes $217,000 Position in Kezar Life Sciences, Inc. (NASDAQ:KZR) - Defense World
Q2 EPS Estimate for Kezar Life Sciences Raised by Analyst - Defense World
Wells Fargo & Company MN Sells 71,985 Shares of Kezar Life Sciences, Inc. (NASDAQ:KZR) - Defense World
KZR Reports Financial Status and Progress in AIH Treatment Trials | KZR Stock News - GuruFocus
Kezar Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update - The Joplin Globe
(KZR) Trading Signals - news.stocktradersdaily.com
Kezar Life Sciences, Inc. (NASDAQ:KZR) Shares Purchased by JPMorgan Chase & Co. - Defense World
Kezar Life Sciences Inc expected to post a loss of $2.60 a shareEarnings Preview - TradingView
Geode Capital Management LLC Lowers Position in Kezar Life Sciences, Inc. (NASDAQ:KZR) - Defense World
Kezar Life Sciences (KZR) Expected to Announce Quarterly Earnings on Thursday - Defense World
(KZR) Technical Data - news.stocktradersdaily.com
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Business Wire
Trend Tracker for (KZR) - news.stocktradersdaily.com
Kezar Life Sciences stock hits 52-week low at $4.36 By Investing.com - Investing.com South Africa
Kezar Life Sciences stock hits 52-week low at $4.36 - Investing.com
Polymyositis Market Predicted to See Upsurge Through 2034, - openPR.com
Kezar Life Sciences Appoints New Principal Accounting Officer - TipRanks
What is William Blair’s Forecast for KZR Q1 Earnings? - Defense World
KZR stock touches 52-week low at $5.20 amid market challenges By Investing.com - Investing.com South Africa
KZR stock touches 52-week low at $5.20 amid market challenges - Investing.com Australia
Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results - BioSpace
Kezar reports positive AIH trial results, financials for 2024 By Investing.com - Investing.com South Africa
Promising Clinical Trial Results and Safety Profile Justify Buy Rating for Kezar Life Sciences - TipRanks
Kezar stock drops on Q4 results, trial data (KZR:NASDAQ) - Seeking Alpha
Kezar Life Sciences Touts Positive Data From Mid-Stage Study For Chronic Liver Disease Drug Candidate - Benzinga
Kezar reports positive AIH trial results, financials for 2024 - Investing.com India
Kezar Life Sciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
KEZAR LIFE SCIENCES Earnings Results: $KZR Reports Quarterly Earnings - Nasdaq
Breakthrough in Autoimmune Hepatitis: Kezar's Drug Achieves 36% Response Rate While Placebo Shows Zero - Stock Titan
Kezar Life Sciences to Present Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis on March 25, 2025 - BioSpace
Major Clinical Trial Results: New Autoimmune Hepatitis Treatment Shows PromiseData Reveal Coming - Stock Titan
Amundi Sells 74,019 Shares of Kezar Life Sciences, Inc. (NASDAQ:KZR) - Defense World
KEZAR LIFE SCIENCES INC- The GF Score's 5 Key Aspects of Analysis - GuruFocus.com
How the (KZR) price action is used to our Advantage - news.stocktradersdaily.com
Dermatomyositis Drug Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Treatment Market, Prevalence, Medication, Statistics, Therapies, Companies by DelveInsight - The Globe and Mail
Kezar Life Sciences Inc expected to post a loss of $2.88 a shareEarnings Preview - TradingView
Kezar Life Sciences’ (KZR) Outperform Rating Reiterated at William Blair - Defense World
Kezar Life Sciences Inc Azioni (KZR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.91%
1.17%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):